Nanoz, a French deeptech company specialising in the design of miniaturised and intelligent sensors, is partnering with academic institutions including Indiana University, University of Sheffield and the CNRS laboratory in Marseille to help detect diabetes and other diseases through breath analysis.
Using AI and sensors no larger than 2mm, the company is developing technology that promises early, non-invasive diagnostics, with potential implications for health systems.
At the heart of Nanoz innovation is a selective nanogas sensor based on MOx (Metal Oxide Semiconductor) technology, developed in collaboration with the Materials, Microelectronics and Nanosciences Institute of Provence (IM2NP – CNRS / Aix-Marseille University).
Nanoz combines these MOx sensors with AI and proprietary databases, to precisely detect gas and identify complex odours and multi-gas signatures. The technology requires no recalibration, ensures long-term reliability, and is protected by an exclusive worldwide CNRS patent.
“Most miniaturised gas sensors lose accuracy when scaled down. We have solved this technological challenge by developing MOx sensors that are both miniaturised and selective. Combined with artificial intelligence and our proprietary databases, this technology can also recognise odour signatures or biomarkers linked to certain diseases, opening the door to new applications in healthcare, industry, and air quality monitoring,” said Thibaud Sellam, founder and CEO of Nanoz.
Thanks to their size (approximately 2 mm) and low energy consumption, Nanoz sensors can be integrated into environments where traditional sensors are too large or energy-intensive. Other applications include consumer electronics, automotive applications, industry and more.
